Biocon Biologics CEO On Interchangeability Dynamics For Humira Biosimilar
Ustekinumab, Denosumab And Pertuzumab Biosimilars Progress
Executive Summary
Biocon Biologics’ CEO indicates that interchangeability may not be pivotal to commercial success in the US for biosimilar adalimumab and that the firm’s Humira rival “checks the key boxes.”
You may also be interested in...
Biocon: Slow Humira Biosimilar Uptake But Payer Landscape Evolving
Biocon bets on dual pricing strategy in the US amid a “more gradual” than expected uptake of biosimilar adalimumab but emphasizes that payer positions aren’t “definitive” yet.
Biocon: Slow Humira Biosimilar Uptake But Payer Landscape Evolving
Biocon bets on dual pricing strategy in the US amid a “more gradual” than expected uptake of biosimilar adalimumab but emphasizes that payer positions aren’t “definitive” yet.
Biocon Pumps Up For Adalimumab US Debut Amid Payer ‘Steady State’
Biocon is confident of its “four channel strategy” for the upcoming debut of biosimilar Humira in the US and also asserts it’s well positioned to compete when price cuts come into play for Sanofi’s Lantus next year.